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Abstract This review of tuberculosis epidemiology is
intended to provide a historical perspective on the public
health approach to tuberculosis (TB) control in California.
This historical context offers a lens through which to view
current epidemiologic trends and insight into how new thera-
peutic tools can be applied. Since 1993, the year detailed case
reporting was instituted, California has had a decrease in re-
cent TB transmission as evidenced by a reduction in pediatric
cases and an increased percentage of cases attributable to pro-
gression of latent infection to TB disease in the foreign-born
population. Overall, there has been a dramatic decline in the
annual TB case count, but the speed of the decline has slowed
over the last several years. At the current pace and case count
of 2137 in 2015, California will not achieve TB elimination
(<1 TB case per one million population) for at least 100 years.
There are an estimated 2.1 million persons in California with
latent TB infection. Modeling suggests that LTBI detection
and treatment are important in reaching TB elimination. For
this reason, a coalition of stakeholders in California is explor-
ing novel approaches to accelerate the case decline in order to
prevent unnecessary disease and death.
Keywords Tuberculosis . TB elimination . Tuberculosis
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Introduction
From the gold rush of the 19th century to the Silicon Valley
tech boom of the 21st century, the BCalifornia Dream,^ has
drawn millions to the state. Throughout California history,
tuberculosis (TB) has been a counterpoint to this dream for a
brighter future. Despite remarkable progress against TB over
the last 100 years, TB is still diagnosed in California every 4 h.
Every other day, a Californian dies with TB, and each week, at
least one child under five is found to have TB disease. At a
time when tuberculosis is a leading killer among infectious
diseases worldwide [1], infecting approximately 1/3 of the
world’s population [2], TB paradoxically has become less
visible in the USA, competing with waves of newer pathogens
that make daily headlines. The fact that TB still causes pre-
ventable deaths and disease deserves an invigorated response.
This report describes the history and epidemiology of TB in
California and presents new strategies that can lead toward the
dream of TB elimination (<1 TB case per one million popu-
lation) in California [1].
The Pathogen
Tuberculosis is caused by the slow-growing microbe,
Mycobacterium tuberculosis. The pathogen has achieved its
success, in part, because of its ability to lurk for many years in
its host before escaping immune system control and multiply-
ing to the point of causing serious harm. Once ill and
coughing, the person suffering from tuberculosis disease be-
comes contagious and the pathogen is spread through droplets
released into the air. Just as it was invisible in the body for
years, it is transmitted without notice to those who breathe in
the droplets coughed out by the ill tuberculosis patient. Once
inhaled, the bacteria take up residence in the lungs. However,
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for up to 90 % of those infected, the bacteria are kept in check
by the host’s immune system in a latent stage throughout life.
For approximately 5–10 % of these infected hosts with latent
TB infection (LTBI), the immune system will not be able to
contain the infection and replicating TB bacteria will cause
illness (active TB disease).
History of the Tuberculosis Epidemic in California
In 1910, the population of California was 2.3 million, less than
10 % of what it is today [3]. During this time period, TB
caused one in seven deaths and was a more visible killer than
cancer and heart disease [4]. Known as consumption, it was
familiar to the rich and the poor, the native Californian, and
the newcomer. The California Tuberculosis Commission of
the State Board of Health described an all too common trag-
edy in California: Bin one family where parents and five chil-
dren occupied a one-room shack, all but two died of TB in
quick succession^ [4]. Even before robust public health sur-
veillance, statistics showed TB’s impact in California. A total
of 644 TB cases and 453 TB deaths were reported in a single
month of 1913 [4]. Measles, scarlet fever, typhoid fever, diph-
theria, meningitis, polio, and smallpox all trailed much further
behind, with deaths from each of these communicable dis-
eases combined adding to less than one eighth of the number
of deaths caused by TB [4].
Public Health Response
The effect of TB on California communities triggered one of
the state’s most effective public health responses. TB disease
and death, and its economic impact, shifted from a household
conversation to a serious focus among doctors and govern-
ment agencies. In 1913, the state health commission launched
a structured investigation of the TB problem and reported that,
Bconstantly present in this state is [sic] between 40,000 and
50,000 tuberculous patients in active stages^ [4]. TB was the
leading cause of premature death, and the average age of death
from TB was 30. The Commission counted 5000 deaths each
year in California and noted that each death terminated only
after many months or years of suffering during which the
disease could be spread to others [4].
The economic consequences of TB were also noticed. The
Commission estimated that the cost of TB to California was
over $20 million ($478.8 million in 2015 dollars) each year
[4]. Families were devastated and became homeless when the
primary wage earner died or could no longer work. Many
persons turned to welfare programs and the government
invested in the support of Californians with TB and in the
hospitals that cared for them.
Medical and public health infrastructure became stronger
and concentrated on detecting TB and averting its spread. By
1920, there were well over 100 TB hospitals and sanatoria
operating in California. Isolation of TB patients in sanatoria
removed many contagious persons from crowded urban and
congregate settings. Laws that required doctors to report TB to
public health authorities and that compelled isolation helped
to interrupt transmission and set the stage for local and state
public health programs as well as the modern public health
surveillance systems we have today. These public health pro-
grams were central in the execution of the state TB commis-
sion recommendations.
TB among cattle was also recognized as interconnected to
the human TB epidemic. According to the Commission, in
1913, 15–30 % of cows were infected with tuberculosis [4].
Consumption of raw dairy products was thought to be the
source of 10–30% of TB cases in humans [5]. The eradication
of bovine TB was initially thought an impossible feat but
proved pivotal in driving down TB in humans [5].
Eradication involved federal, state, and local governments
and massive testing and culling of cows. Transmission to
humans was curtailed by instituting pasteurization. While
raw milk was the only milk consumed in 1900, commercially
available pasteurized milk became the norm by 1936 [5].
The gains produced by these public health interventions
were augmented by development of effective antituberculosis
therapy. Especially after the middle of the 20th century when
multidrug treatment became available [6], TB disease was
driven down further and death became a fate for a minority
of those with TB. Treatment shifted from inpatient to outpa-
tient settings. Hospitals, once crowded with TB patients, be-
came sites of care for TB patients with advanced or life-
threatening illness. The TB-specific interventions coincided
with other advances affecting general health and healthcare
which also likely made a difference. For example, improved
nutrition may have reduced progression of latent TB infection
to TB disease and improved housing and working conditions
may have reduced transmission. As a result, from 1913 to
1981, there was a 60 % drop in TB cases and a >90 % drop
in the rate of TB in California expressed as cases per 100,000
population.
However, during the 1980s, the public health infrastructure
that was built up previously in the century was neglected [7].
Categorical funding for US TB control programs was halted
beginning in 1970. The resource shift away from TB control
was followed by a large increase in TB cases in the USA and
California (Fig. 1). Several factors contributed to the increase,
including a surge in immigration of persons with infection
from high burden countries, the vulnerability of HIV-
infected persons with weakened immune systems, and
relaxing of public health measures and infection control. It
became clear that the availability of effective antituberculosis
drugs without the ongoing support of public health
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interventions was not enough to keep TB in check. Once
again, government, doctors, and public health programs need-
ed to work together to fight TB.
What ensued was an intensive investment in hospital infec-
tion control measures and support for patients to continue TB
treatment safely after discharge from the hospital. Investments
also included fiscal resources to strengthen local TB programs,
expanded coverage of indigent populations with TB by the
state’s Medicaid program, and use of new strategies to enable
completion of treatment such as housing of homeless patients
and directly observed therapy. A more robust TB surveillance
system was implemented in 1993 that included reporting of
drug susceptibility and TB treatment outcomes. More recently,
improvements in immigrant screening have made an additional
important dent in case numbers in California [8, 9].
Current Epidemiology
Today, with approximately 40 million residents, California is
the most populous state in the nation and arguably the most
diverse [10]. Its large population differs in composition from
populations in other states and reflects the migration patterns
and countries of origin of migrants over time. Approximately
10 million or 20 % of Californians were born outside the US
with Mexico, Philippines, China, and Vietnam being the most
common birth countries. California’s foreign born population
represents approximately 25 % of all foreign born persons
living in the USA, and half of all children in California have
at least one foreign born parent [11].
There are more than 2100 TB cases reported in California
each year, contributing 20–25 % of the tuberculosis reported
annually in the USA. More than 75 % of TB cases in
California occur among foreign-born persons. TB cases in
California arise through three general mechanisms: importa-
tion of active disease from outside the USA, active disease
occurring as a result of recent transmission of TB within
California, and reactivation of infection acquired long ago.
During 2010–2014, 7.5 % of cases occurred among immi-
grants within 1 year of arrival in the USA. An additional
13 % occurred as a result of recent transmission as defined
by the CDC [12]. The remaining nearly 80 % of TB cases in
California arose from progression of latent infection to active
disease in persons who acquired infection a long time ago and
typically far away from California.
Change in Characteristics of TB Cases in California
1993–2014
Since detailed case reporting was instituted for tuberculosis in
1993, substantial progress has been made in controlling tuber-
culosis. This progress can be seen in the differences between
the number and characteristics of cases reported during 1993–
1997 compared with cases reported during 2010–2014.
Table 1 shows these differences in demographics, clinical
characteristics, and outcomes compared using the Chi-square
test. Fewer cases are occurring among children, incarcerated
persons, and the homeless. These trends are signs of decreas-
ing transmission of TB in California. A smaller percent of TB
cases are infected with HIV, likely the result of improved
infection control practices, screening of HIV-positive persons,
and most importantly, the advent and widespread use of anti-
retroviral therapy. The small increase in the proportion of TB
cases that occur among healthcare workers is explained by an
increase in TB cases among foreign-born healthcare workers.
This is likely related to changing healthcare workforce that
now includes more foreign-born persons [13].
There were few meaningful changes in drug susceptibility
patterns ofM. tuberculosis isolates in 1993–1997 compared with
2010–2014. Pansusceptible (susceptible to INH, rifampin (RIF),
and pyrazinamide (PZA), if tested) and INH-resistant cases
remained stable. However, PZA monoresistance has increased
(5.1 vs. 1.5 %). PZA monoresistance is primarily attributed to
cases caused byMycobacterium bovis, which has been shown to
















































































Fig. 1 Tuberculosis cases and
case rates―California, 1930–
2015
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Table 1 Characteristics of reported tuberculosis cases in California during 1993–1997 compared with 2010–2014
1993–1997 2010–2014






Age 42f (28, 60)g 51f (33, 67)g <0.0001
Age, foreign-born 42f (28, 62)g 54f (37,69)g <0.0001
Age, US-born 41f (27, 58)g 39f (20, 59)g 0.0040
Children (aged <15 years) 2120 (9.2) 496 (4.5) <0.0001
Foreign-born 14,992 (65.5) 8707 (78.3) <0.0001
Site of disease <0.0001
Pulmonary only 17,324 (75.4) 7605 (68.3)
Pulmonary + extrapulmonary 1264 (5.5) 1171 (10.5)
Extrapulmonary only 4382 (19.1) 2355 (21.2)
Cavitary disease (among pulmonary cases) a 3718 (20.8) 1803 (21.7) 0.1280
Sputum smear + disease (among pulmonary cases)a 7392 (45.7) 4476 (54.8) <0.0001
Not culture-positive (among all cases) 5670 (24.7) 2192 (19.7) <0.0001
Medical risk factors for TB
HIV infected 1956 (8.5) 454 (4.1) <0.0001
Diabetes d 2579 (23.2)
End-stage renal disease d 410 (3.7)
TNF-alpha d 93 (0.8)
Organ Transplant d 83 (0.8)
Other immunosuppression d 668 (6.0)
Any medical risk factor (includes HIV) d 3671 (33.0)
Social risk factors for TB
Diagnosed in Corrections 943 (4.1) 349 (3.1) <0.0001
Homeless 1770 (8.4) 588 (5.3) <0.0001
Drug use 1775 (9.6) 725 (6.6) <0.0001
Excessive alcohol use 2504 (13.9) 918 (8.4) <0.0001
Healthcare worker 383 (1.7) 419 (3.8) <0.0001
US-born healthcare worker 122 (0.5) 70 (0.6)
Foreign-born healthcare worker 260 (1.1) 349 (3.1)
Drug resistanceb <0.0001
Pansusceptible (includes EMB monoresistance) 14,421 (87.4) 7443 (84.5)
INH monoresistance 1279 (7.8) 716 (8.1)
Rifampin monoresistance 101 (0.6) 17 (0.2)
PZA monoresistance 248 (1.5) 445 (5.1)
Polydrug resistance 159 (1.0) 66 (0.8)
MDR 246 (1.5) 103 (1.2)
Pre-XDR 34 (0.2) 15 (0.2)
XDR 5 (0.03) 4 (0.1)
Primary provider of TB carec
Private sector 7094 (32.2) 2361 (35.7) <0.0001
Public TB clinic 10,853 (49.2) 3650 (55.1)
Both public TB clinic and private sector 4109 (18.6) 610 (9.2)
Outcome
Death before treatment start 674 (2.9) 147 (2.2) 0.0005
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Hispanic communities in Southern California and is more
common among children [14]. TB from M. bovis is likely
related to consumption of unpasteurized dairy products made
outside the USA. Despite a global rise in multidrug-resistant
(MDR) TB cases, the proportion of TB cases in California that
are MDR has remained stable at 1–2 % of TB cases. One
explanation for this observation is that very few MDR cases
are being created as a result of acquired resistance from poor
treatment practices in California.
Changes in the age of US-born and foreign-born patients
with TB have gone in opposite directions with the median age
among foreign-born persons increasing from 42 to 54, where-
as the median age of US born TB cases has decreased to 39.
These opposite trajectories likely indicate major differences in
underlying population risks for TB exposure and progression to
active disease. Among foreign-born persons, much TB is
occurring among persons with age-related medical comorbidi-
ties such as diabetes and end-stage renal disease that increase
the risk of progression to active TB disease. TB disease also
typically is occurring among long-standing residents of the
USA with >75 % of TB cases among foreign-born persons
occurring in persons who have been present in the USA for at
least 5 years. In contrast, US-born TB patients aremore likely to
have social or behavioral risk factors for TB such as substance
abuse, incarceration, or homelessness. These populations can
bemore difficult to reach with TB prevention activities and also
may be groups in whom TB transmission is concentrated.
Among the most dramatic changes in TB during 1993–
2014 has been the fall in TB cases from 5150 cases in 1993
to 2137 cases in 2015 (Fig. 1). During the same period, the
annual rate of TB declined from 16.3 to 5.5 per 100,000 pop-
ulation. Sadly, nearly 10 % of persons with TB in California
still die and nearly one third of these died before TB treatment
could be started.
Despite the dramatic decline in TB cases and rates, the
speed of the decline has slowed substantially from an average
6.4 % annual decline from 1993–1997 to an annual case de-
cline of 3.8 % during 2005–2014. In the last two years, the
decline was only 1 % per year. In 2015, there were 2137 cases
of TB reported in California (a rate of 55 cases per million). If
the rate of decline from the last 10 years continues, TB elim-
ination (defined as less than 1 case per one million population)
will not be achieved for 100 years (Table 2). On the other
hand, if the rate of decline can be sped up to 14 % per year,
TB could be eliminated from California by 2040 (Fig. 2).
Modeling studies have shown that speeding the decline will
require addressing the primary source of new TB cases in
Table 1 (continued)
1993–1997 2010–2014






Among patients alive at diagnosis and started on treatmentc <0.0001
Death after treatment start 1828 (8.3) 481 (7.2)
Lost/moved/refused/unknown 2222 (10.1) 389 (5.9)
Moved outside the USA 655 (3.0) 149 (2.2)
Treatment complete 18,050 (81.7) 5772 (86.9)
INH isoniazid, RIF rifampin, PZA pyrazinamide, EMB ethambutol, IQR interquartile range, MDR multidrug resistance, defined as resistance to at least
INH and RIF, Pre-XDR pre-extensively drug resistant, defined as MDR plus resistance to a fluoroquinolone or a second-line injectable medication
(amikacin, capreomycin, or kanamycin); polydrug resistance, defined as resistance to at least two first-line drugs, but not MDR
aDenominator = pulmonary cases with or without extrapulmonary disease
bMutually exclusive categories among cases tested to at least INH and RIF. Includes cases that acquired resistance on treatment
c Denominator = alive at diagnosis and started on treatment. Data in later time period only available for 2010–2012
dOnly available for 2010 and later
e Calculations exclude missing and unknown values from the denominator
f median
g interquartile range
Table 2 Years to TB elimination and pre-elimination in California
Status Rate Cases in California
Current (2015) 55 cases/million 2137
Pre-elimination <10 cases/million 388a
Elimination <1 case/million 39a
a Based on 2014 US Census Estimate of California Population: 38.8
million
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California, latent TB in incoming immigrants as well as
among the population already present in California [15].
Latent TB Infection
In contrast to the epidemiology of TB disease in the USA, the
epidemiology of latent TB infection (LTBI) is based on esti-
mates from survey data because LTBI is not a reportable con-
dition. The National Health and Nutrition Examination
Survey (NHANES) has been used as a primary source to
estimate LTBI prevalence [16]. The NHANES survey has
collected data on TB infection through the use of tuberculin
skin tests (TST) in the 1971–1972 and 1999–2000 surveys
and TST plus interferon gamma release assays (IGRAs) in
the 2011–2012 survey. Miramontes et al. analyzed this data
set finding that 1.5 and 2.8 % of the US-born population was
infected with TB using TST and IGRA, respectively [17••].
However, among foreign-born persons, the prevalence of
LTBI was much higher, estimated at 20.5 % by TST and
15.9 % by IGRA. BCG vaccination, common among
foreign-born persons, can lead to false positive TST reactions
but does not influence IGRA results. That is why IGRA offers
superior accuracy in this population.
In order to estimate the number and proportion of California
residents with LTBI, prevalence estimates from NHANES
2011–2012 were applied to race/ethnicity and nativity strata
derived from California population estimates for 2014 in the
US Census Current Population Survey Annual Social and
Economic Supplement (CPS; available using the online CPS
Table Creator http://www.census.gov/cps/data/cpstablecreator.
html). Using TST for US-born and IGRA for foreign-born
persons yields an estimate of 2,171,673 persons with LTBI,
of which 545,273 are US born and 1,626,400 are foreign born
(Table 3). As noted, the use of IGRA more accurately reflects
true TB infection in the BCG-vaccinated foreign born popula-
tion however IGRA may overestimate through false positive
results the rate of LTBI in the US-born population with a lower
pre-test probability for TB infection [18].
Currently, there are several populations that undergo man-
datory and systematic assessments for TB infection including
approximately 5000 immigrants with abnormal overseas pre-
immigration radiographs receiving follow-up evaluations in
California and 113,000 foreign-born persons who apply to
adjust their immigration status in California to become perma-
nent US residents per year. These groups are at high risk for
TB infection and disease because of the likelihood of exposure
in their country of origin and warrant systematic screening for
TB infection [19]. However, screening and treatment of new
arrivals will not fully address the TB problem in
California because of the large population of foreign-born
persons currently living in California with untreated LTBI.
This is in line with recent data from Walter et al. describing
the ongoing elevated risk of TB reactivation in immigrants
from the Philippines up to 9 years after immigration to
California [20••]. Additionally, California TB surveillance da-
ta indicates that approximately 70 % of 2014 cases in foreign-
born persons occurred in those that immigrated over 10 years
prior to diagnosis.
Despite these findings, until now, there has not been a
recommendation for systematic screening for LTBI in
foreign-born persons living in California. However, many
populations at far lower risk of TB acquisition undergo
systematic screening. Indeed, more than 80 % of the 1,726,
000 individuals undergoing mandatory screening in California
each year are healthcare workers who are legally mandated to
undergo annual screening for TB infection and disease despite
a decrease of TB transmission in hospitals today. The cost-
savings and effectiveness of risk-based TB screening rather
than universal screening, has been demonstrated in other low
risk groups in California including school children and school
teachers [21]. Re-focusing resources on screening populations
at high risk for LTBI provides an opportunity to further reduce






























































* Based on annual rate of decline for 2005-2014
Fig. 2 Years of TB pre-
elimination and elimination in
California. Extrapolation based
on current rate of decline
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Efforts toward TB Elimination
The epidemiology of both active TB and of latent TB infection
in California point toward a strategy to achieve TB elimina-
tion in California involving increased focus on preventing TB
among populations at risk for TB exposure and infection. In
May 2015, the California Department of Public Health
(CDPH) Tuberculosis Control Branch (TBCB) convened the
California TB Elimination Task Force to help craft specific
strategies for TB elimination [22]. The Task Force emphasized
the need for simple and clear guidance to healthcare providers
regarding populations to test for LTBI and treat if infected.
The recommendations promote the use of (1) local epidemio-
logic data to identify and engage populations at risk for TB
infection, with a focus on testing of foreign-born residents,
immunosuppressed persons at high risk for TB progression,
and close contacts to persons with infectious TB [23]; (2) full
adoption and implementation of diagnostics such as the inter-
feron gamma release assay (IGRA) to improve test specificity
and cost-effectiveness in foreign-born populations [24•]; (3)
the use of short-course treatment regimens such as 12 doses of
isoniazid and rifapentine or 4 months of daily rifampin to
increase rates of LTBI treatment completion [25, 26, 27•].
These measures are designed to speed the decline of TB and
decrease the time to TB elimination in California.
Several new opportunities make this a good time to push
toward TB elimination: (1) the recently introduced short treat-
ment regimen for LTBI (12 dose regimen of INH/rifapentine)
has impressive completion rates [13, 27•] resulting in more
TB disease prevented; (2) the interferon gamma release as-
says, while imperfect, add value and efficiency in detecting
latent TB infection in the foreign born since false positives due
to BCG do not occur; (3) the expansion of healthcare coverage
in California provides access to care for many who previously
were not engaged in care and who will benefit from TB pre-
vention; and (4) new national and international understanding
of the importance of addressing the LTBI reservoir to advance
toward TB elimination [1]. Indeed, a model by Hill et al.
suggests that if testing and treating LTBI were increased four-
fold, along with reduction of untreated LTBI among new ar-
rivers to the USA, TB cases can be reduced approximately
tenfold by 2040 [15].
The ambition to reach elimination in the next 15 years has
been stimulated by both evidence and pragmatic consider-
ations. Reaching elimination in California by 2040 will re-
quire a 14 % annual decline in TB cases. The steepest decline
in a given year in California in the past two decades was 11 %,
a value relatively close to 14 %. This value is however more
than threefold higher than the recent 5-year average annual
decline. How would this change in case decline be feasible?
Since little investment has been made to date in systematically
testing for and treating LTBI in high risk individuals, an in-
vestment now is likely to increase the case decline significant-
ly. In addition, progress has been made globally with declines
in TB disease and deaths in many regions [1]. Indeed, the
WHO has set ambitious TB elimination goals in their plans
for low incidence countries [20••].
Currently, TB disease is at a historic low. Many ask wheth-
er it is worthwhile to make an investment in elimination if we
expect to eventually get there, albeit in 100 years. For each
year in which our case decline does not accelerate, we lose
over 200 Californians to TB and spend millions of dollars on
direct TB services alone. TB deaths are not inevitable deaths,
they are preventable deaths. If we achieve TB elimination in
Table 3 Estimated prevalence of




Total 6.1% 38,802,500 2,380,068
US born (all) 1.9 % 27,920,749 542,765
White (non-Hispanic/Latino) 0.7 % 13,933,084 97,532
Black (non-Hispanic/Latino) 5.1 % 2,490,359 127,008
Hispanic/Latino 2.9 % 9,070,625 263,048
Asian 2.4 % 2,086,289 50,071
Other (non-Hispanic/Latino) 1.5 % 340,392 5,106
Foreign-born (all) 16.9 % 10,881,751 1,837,303
White (non-Hispanic/Latino) 9.4 % 1,619,862 152,267
Black (non-Hispanic/Latino) 15.2 % 193,964 29,483
Hispanic/Latino 15.6 % 5,392,958 841,301
Asian 22.3 % 3,592,700 801,172
Other (non-Hispanic/Latino) 15.9 % 82,267 13,080
a Based on National Health and Nutrition Examination Survey, 2011–2012, as reported by Miramontes et al. [16]
using tuberculin skin test for US born and interferon gamma release assay for foreign born (population estimate
from US Census American Community Survey)
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2040, instead of 2115, we would prevent 4200 deaths and 42,
411 cases. Among the millions in California with TB infec-
tion, most are not aware they are infected but deserve to know
and to have an opportunity to prevent disease from occurring.
Challenges
In the process of intensifying testing and treatment of latent
TB infection, there is some fear that these public health efforts
could shift focus away from core TB control activities such as
early diagnosis, effective treatment of TB disease, and contact
investigation. Continuing these activities while also tackling
TB prevention will be a challenge, but one that can be met
with cooperation between the healthcare and public health
system. Another challenge to TB elimination is that
Californians regularly travel to and migrate from world re-
gions with higher rates of TB. However, by working with
Federal partners, we may be able to make additional progress.
A change in TB screening programs for new immigrants and
those adjusting their immigration status to identify LTBI and
encourage treatment may result in further case decline. Last,
and most important for the world as a whole, is WHO’s elim-
ination plan and serious campaign to achieve zero TB deaths
[28]. This indeed is a bold change for a disease that is a top
killer in so many countries.
Many questions arise about how to normalize testing and
treatment of LTBI in primary care and ensure timely detection
and treatment of TB disease when it occurs in the setting of
waning experience with TB. The current pressures on the busy
clinical practitioner to be everything to everyone while pro-
viding a meaningful visit for the person seeking care are
daunting. Nevertheless, routinely screening for TB risk and
then testing those with risk and ensuring treatment of those
infected must occur for TB elimination to become possible.
Since the California population is large, new efforts and in-
vestments are needed to help make this possible in primary
care settings.
Future Research Directions
Despite recent progress in LTBI testing and treatment, the
research to deliver improved tests for infection and really rap-
id treatment of both LTBI and TB disease stand as the two
most critical needs beyond an effective vaccine. Neither
IGRA nor TST are highly predictive of progression from
LTBI to active disease. Operational research is needed to de-
termine the most effective approaches to screening of LTBI. In
parallel, investments globally to reach the millions with dis-
ease and infection are paramount.
Conclusions
California leads in population size and in the number of TB
cases reported in the USA. Yet we dream of a state that has
abundance of people and diversity, but without a threat of
disease such as TB. In 2016, California has an unprecedented
opportunity to make progress toward TB elimination. TB dis-
ease is at a historic low point and the risk of developing new
TB infection in California is now small. The introduction of
new shorter treatment regimens for latent TB infection makes
preventing TB disease much easier. The trick will be to focus
testing and treatment while making it routine. The dream of
children living without the terrifying infectious diseases of
polio and smallpox has been realized. This is a dream we feel
is worth pursuing for tuberculosis.
Acknowledgments We thank the California local tuberculosis pro-
grams for contributing data for tuberculosis surveillance, Peter Oh and
Janice Westenhouse for assistance with data analysis, and Joanna Lu for
assistance with manuscript preparation.
Compliance with Ethical Standards
Funding This publication was supported in part by the Cooperative
Agreement U52PS004656, funded by the Centers for Disease Control
and Prevention. Its contents are solely the responsibility of the authors
and do not necessarily represent the official views of the Centers for
Disease Control and Prevention or the Department of Health and
Human Services.
Conflict of Interest Pennan M. Barry, Alexander W. Kay, Jennifer M.
Flood, and James Watt declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. World Health Organization. Global tuberculosis report 2015. 2015.
http://www.health-e.org.za/wp-content/uploads/2015/10/Global-
TB-Report-2015-FINAL-2.pdf. Accessed 16 Feb 2016.
Curr Epidemiol Rep (2016) 3:136–144 143
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global
burden of tuberculosis: estimated incidence, prevalence, and mor-
tality by country. JAMA. 1999;282:677–86.
3. United States Census Bureau. Resident population and apportion-
ment of the U.S. house of representatives. https://www.census.gov/
dmd/www/resapport/states/california.pdf. Accessed 19 Feb 2016.
4. Report of the California tuberculosis commission of the state board
of health. Sacramento: California State Printing Office; 1914.
5. Olmstead AL, Rhode PW. An impossible undertaking: the eradica-
tion of bovine tuberculosis in the United States. J Econ Hist.
2004;64:734–72.
6. Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tubercu-
losis, a historical perspective. Ann Am Thorac Soc. 2015;12:1749–
59.
7. Committee on the Elimination of Tuberculosis in the United States,
Lawrence G (editor). Ending neglect: the elimination of tuberculo-
sis in the United States. Washington D.C.: Institute of Medicine.
2000.
8. Lowenthal P, Westenhouse J, Moore M, Posey DL, Watt JP, Flood
J. Reduced importation of tuberculosis after the implementation of
an enhanced pre-immigration screening protocol. Int J Tuberc Lung
Dis. 2011;6:761–6.
9. Liu Y, Painter JA, Posey DL, Cain KP,WeinbergMS,Maloney SA,
et al. Estimating the impact of newly arrived foreign-born persons
on tuberculosis in the United States. PLoS One. 2012. doi:10.1371/
journal.pone.0032158.
10. United States Census. 2010 Census Shows America's Diversity
Press Release. 2011. https://www.census.gov/newsroom/releases/
archives/2010_census/cb11-cn125.html. Accessed 18 Feb 2016.
11. Hans J, Mejia MC. Just the facts: immigrants in California. Public
Policy Institute of California. 2013. http://www.ppic.org/main/
publication_show.asp?i=258. Accessed 12 Jan 2016.
12. France AM, Grant J, Kammerer JS, Navin TR. A field-validated
approach using surveillance and genotyping data to estimate tuber-
culosis attributable to recent transmission in the United States. Am J
Epidemiol. 2015;182:799–807.
13. Lowell BL. The foreign born in the American healthcare workforce:
trends in this century’s first decade and immigration policy. Paper
prepared for presentation at conference on BMigration and
Competitiveness: Japan and the United States^ at the University
of California at Berkeley, March 2012. 2012. https://
migrationfiles.ucdavis.edu/uploads/rs/files/2012/9/ciip/lowell-us-
health-care.pdf. Accessed 19 February 2016.
14. Gallivan M, Shah N, Flood J. Epidemiology of human
Mycobacterium bovis disease, California, USA, 2003–2011.
Emerg Infect Dis. 2015;21:435–43.
15. Hill AN, Becerra J, Castro KG.Modelling tuberculosis trends in the
USA. Epidemiol Infect. 2012;140:1862–72.
16. Centers for Disease Control and Prevention. NHANES 2011–2012
overview. National Center for Health Statistics. 2014. http://www.
cdc.gov/nchs/nhanes/nhanes2011-2012/overview_g.htm. Accessed
10 Jan 2016.
17.•• Miramontes R, Hill AN, Yelk Woodruff RS, Lambert LA, Navin
TR, Castro KG, et al. Tuberculosis infection in the United States:
prevalence estimates from the national health and nutrition exami-
nation survey, 2011–2012. PLoS One. 2015. doi:10.1371/journal.
pone.0140881. This article provides an estimate of the
prevalence of latent TB infection (LTBI) in the USA based on
data from the National Health and Nutrition Evaluation Survey
(NHANES). The magnitude of the US population with LTBI is
large—13,276,000 persons (or 4.3% of the US population). The
prevalence of TB infection is lower among the US-born popu-
lation (2.8 %) than among foreign-born population (15.9%) as
estimated by IGRA results.
18. Slater ML, Welland G, Pai M, Parsonnet J, Banaei N. Challenges
with QuantiFERON-TB Gold assay for large-scale, routine screen-
ing of U.S. healthcare workers. Am J Respir Crit Care Med.
2013;188:1005–10.
19. Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE.
Cost-effectiveness of tuberculosis evaluation and treatment of
newly-arrived immigrants. BMC Public Health. 2006. doi:10.
1186/1471-2458-6-157.
20.•• Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, et al.
Persistent latent tuberculosis reactivation risk in United States im-
migrants. Am J Respir Crit Care Med. 2014;189:88–95. This arti-
cle estimates the reactivation risk and persistence of elevated
TB rates of immigrants from the Philippines to California.
The rate of latent tuberculosis infection (LTBI) reactivation
did not decline over an 8-year period suggesting a persistent
high risk of LTBI reactivation for these immigrants. Authors
suggest that guidelines should support LTBI screening and
treatment even after the 5-year post-arrival to the USA.
21. Flaherman VJ, Porco TC, Marseille E, Royce SE. Cost-
effectiveness of alternative strategies for tuberculosis screening be-
fore kindergarten entry. Pediatrics. 2007;120:90–9.
22. California Department of Public Health, California Tuberculosis
Controllers Association, University of California San Francisco.
Report of the California tuberculosis elimination task force meet-
ing, 2015. 2015. http://www.cdph.ca.gov/programs/tb/Documents/
TBCB-Report-CA-TB-Elimination-Task-Force-Meeting-2015.pdf.
Accessed 19 Feb 2016.
23. California Department of Public Health, Curry International
Tuberculosis Center, California Tuberculosis Controllers
Association. California tuberculosis risk assessment. 2015. http://
www.cdph.ca.gov/programs/tb/Documents/TBCB-CA-TB-Risk-
Assessment-and-Fact-Sheet.pdf. Accessed 12 Feb 2016.
24.• Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for
screening and treatment of latent tuberculosis infection in the
United States. Am J Respir Crit Care Med. 2011;184:590–601.
This article describes models of cost-effectiveness of TB screen-
ing, strategy testing, and treatment among the foreign-born
population. Findings suggested that latent tuberculosis infection
(LTBI) screening can help achieve TB elimination by prioritiz-
ing screening of close contacts, HIV-infected individuals, and
foreign-born populations.
25. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B,
et al. Treatment for preventing tuberculosis in children and adoles-
cents: a randomized clinical trial of a 3-month, 12-dose regimen of a
combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:
247–55.
26. Cruz AT, Starke JR. Safety and completion of a 4-month course of
rifampicin for latent tuberculous infection in children. Int J Tuberc
Lung Dis. 2014;18:1057–61.
27.• Sterling TR, VillarinoME, Borisov AS, ShangN, Gordin F, Bliven-
Sizemore E, et al. Three months of rifapentine and isoniazid for
latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.
This article describes the results of a clinical trial involving a
12-dose regimen of isoniazid and rifapentine for latent tubercu-
losis infection (LTBI) treatment. The results demonstrate that
12 weekly doses of rifapentine and isoniazid resulted in a higher
treatment completion rate and were as effective as isoniazid
alone for 9 months.
28. Stop TB Partnership. Global plan to end TB: the paradigm shift
2016–2020. 2015. http://www.stoptb.org/assets/documents/global/
plan/GlobalPlanToEndTB_TheParadigmShift_2016-2020_
StopTBPartnership.pdf. Accessed 19 Feb 2016.
144 Curr Epidemiol Rep (2016) 3:136–144
